Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Decrease in Short Interest

Kazia Therapeutics Limited (NASDAQ:KZIA) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 22,300 shares, a drop of 36.3% from the November 15th total of 35,000 shares. Based on an average daily trading volume, of 146,500 shares, the short-interest ratio is currently 0.2 days.

Kazia Therapeutics Trading Down 3.3 %

Shares of NASDAQ:KZIA traded down $0.12 during trading on Friday, reaching $3.55. 44,207 shares of the company traded hands, compared to its average volume of 404,454. The firm has a fifty day simple moving average of $5.03 and a 200 day simple moving average of $4.10. Kazia Therapeutics has a 1-year low of $1.87 and a 1-year high of $15.80.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management bought a new position in Kazia Therapeutics Limited (NASDAQ:KZIA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned 51.66% of Kazia Therapeutics at the end of the most recent reporting period. 30.89% of the stock is currently owned by institutional investors and hedge funds.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.